drugset / Trial / NCT02516813
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Phase 1
Completed
52 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
M3814 was an investigational drug that is being evaluated for the treatment of participants with locally advanced tumors. The main purposes of this study was to determine the safety, the tolerability and the efficacy of M3814 in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).
Timeline
- Start
- 2015-09-15
- Primary completion
- 2021-03-26
- Completion
- 2021-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEDISERTIB | Small molecule | 50 mg | Oral |
| Subject | NEDISERTIB | Small molecule | 100 mg | Oral |
| Subject | NEDISERTIB | Small molecule | 200 mg | Oral |
| Subject | NEDISERTIB | Small molecule | 300 mg | Oral |
| Subject | NEDISERTIB | Small molecule | 400 mg | Oral |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |